[go: up one dir, main page]

MX2009003518A - Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar. - Google Patents

Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.

Info

Publication number
MX2009003518A
MX2009003518A MX2009003518A MX2009003518A MX2009003518A MX 2009003518 A MX2009003518 A MX 2009003518A MX 2009003518 A MX2009003518 A MX 2009003518A MX 2009003518 A MX2009003518 A MX 2009003518A MX 2009003518 A MX2009003518 A MX 2009003518A
Authority
MX
Mexico
Prior art keywords
tgf
risk
antagonists
bronchopulmonary dysplasia
period
Prior art date
Application number
MX2009003518A
Other languages
English (en)
Inventor
James B Streisand
Jesse D Roberts Jr
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2009003518A publication Critical patent/MX2009003518A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La descripción se relaciona a métodos para tratar a un infante en riego de desarrollar displasia broncopulmonar, incluyendo infantes prematuros, al administrar un antagonista de TGF-ß durante el periodo perinatal, incluyendo el periodo prenatal y/o el periodo postnatal. Para la administración durante el periodo prenatal, el antagonista de TGF-ß puede ser administrado ya sea directamente al infante en el útero, o indirectamente por administración a la madre.
MX2009003518A 2006-10-03 2007-10-03 Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar. MX2009003518A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82793306P 2006-10-03 2006-10-03
PCT/US2007/021234 WO2008060371A1 (en) 2006-10-03 2007-10-03 USE OF TGF-β ANTAGONISTS TO TREAT INFANTS AT RISK OF DEVELOPING BRONCHOPULMONARY DYSPLASIA

Publications (1)

Publication Number Publication Date
MX2009003518A true MX2009003518A (es) 2009-08-25

Family

ID=39217964

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003518A MX2009003518A (es) 2006-10-03 2007-10-03 Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.

Country Status (10)

Country Link
US (3) US8642034B2 (es)
EP (3) EP2083863B1 (es)
CN (2) CN104645328A (es)
DK (2) DK2083863T3 (es)
ES (2) ES2538265T3 (es)
HU (1) HUE035575T2 (es)
IL (2) IL197797A (es)
MX (1) MX2009003518A (es)
PL (2) PL2918288T3 (es)
WO (1) WO2008060371A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140134181A1 (en) * 2010-11-05 2014-05-15 Kenneth E. Lipson Treatment Method For Lung Remodeling Diseases
EP3382391A1 (en) 2012-10-24 2018-10-03 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
LT2971048T (lt) 2013-03-11 2019-02-25 Genzyme Corporation Inžineriniu būdu gauti anti-tgf-beta antikūnai ir antigeną surišantys fragmentai
EP3816625B1 (en) 2013-05-06 2025-09-17 Scholar Rock, Inc. Compositions and methods for growth factor modulation
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
CN116327952A (zh) 2015-08-04 2023-06-27 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
US10500203B2 (en) 2015-09-09 2019-12-10 Rush University Medical Center Compositions and methods for treating bone diseases
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
AU2018261131A1 (en) 2017-05-04 2019-11-07 Acceleron Pharma Inc. TGF-beta receptor type II fusion proteins and uses thereof
WO2019055661A1 (en) 2017-09-13 2019-03-21 Progenity, Inc. PRE-ÉCLAMPSIE BIOMARKERS AND ASSOCIATED SYSTEMS AND METHODS
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS606629A (ja) 1983-06-23 1985-01-14 Sumitomo Chem Co Ltd ホルムアルデヒドの製造法
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
JP2887325B2 (ja) * 1988-06-28 1999-04-26 ラ ホヤ キャンサー リサーチ ファウンデーション デコリンによる細胞増殖の抑制
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5583103A (en) 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
DK0494264T3 (da) 1989-09-29 1998-01-26 Jolla Cancer Res Found Inhibering af transformede vækstfaktor til hindring af akkumulation af ekstracellulær matrix
AU639047B2 (en) 1989-11-22 1993-07-15 Genentech Inc. Latency associated peptide and uses therefor
WO1991010727A1 (en) 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
FR2677038B1 (fr) * 1991-06-03 1994-08-12 Bel Fromageries Additif alimentaire pour l'alimentation humaine et animale et aliments le contenant.
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
AU671606B2 (en) 1991-10-31 1996-09-05 Whitehead Institute For Biomedical Research TGF-beta type receptor cDNAs and uses therefor
AU673506B2 (en) 1991-11-14 1996-11-14 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
AU5587094A (en) 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
WO1994009815A1 (en) 1992-10-29 1994-05-11 Celtrix Pharmaceuticals, Inc. USES OF TGF-β RECEPTOR FRAGMENT AS A THERAPEUTIC AGENT
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
EP0667870A4 (en) 1992-10-30 1998-04-01 Hsc Res Dev Lp COMPOSITIONS AND METHODS FOR MODIFYING THE REGULATORY ACTIVITY OF TGF--g(b).
JP3555952B2 (ja) 1993-04-30 2004-08-18 バイオグノスティック・ゲゼルシャフト・フュア・バイオモレキュラーレ・ダイアグノスティック・ミット・ベシュレンクテル・ハフツング トランスフォーミング成長因子−β（ＴＧＦ‐β）の免疫抑制効果の治療用アンチセンス−オリゴヌクレオチド類
AU6984594A (en) 1993-06-15 1995-01-17 Hun Taeg Chung Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
WO1995010610A1 (en) 1993-10-15 1995-04-20 La Jolla Cancer Research Foundation BETAGLYCAN POLYPEPTIDES HAVING TGF-β BINDING ACTIVITY
JPH09512910A (ja) 1994-05-04 1997-12-22 マウント・サイナイ・ホスピタル・コーポレイション ＴＧＦ−βスーパーファミリーのサイトカインの変調因子およびそのアッセイ方法
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
JPH08119984A (ja) 1994-08-31 1996-05-14 Nkk Corp ストレプトミセス属放線菌及びこの菌由来のＴＧＦ−β 阻害剤
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2000510112A (ja) 1996-04-30 2000-08-08 ジェンザイム コーポレーション ＴＧＦ―β拮抗物質としてのプロラクチンの使用方法
JPH1067674A (ja) 1996-06-19 1998-03-10 Advanced Sukin Res Kenkyusho:Kk 細胞外マトリツクスの異常蓄積抑制剤
CA2269711A1 (en) 1996-10-25 1998-04-30 Johnson & Johnson Medical, Inc. Anti-fibrotic agent assay
PL336306A1 (en) 1997-04-18 2000-06-19 Biogen Proteinous fusions of tgf-beta ii type receptor with a constant immunoglobulin area
US7779020B2 (en) 2002-03-01 2010-08-17 International Business Machines Corporation Small-footprint applicative query interpreter method, system and program product
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2000047102A2 (en) * 1999-02-11 2000-08-17 The General Hospital Corporation COMPOSITIONS AND METHODS FOR MODULATING TGF-β SIGNALING
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
KR100425525B1 (ko) 2000-11-21 2004-03-30 재단법인서울대학교산학협력재단 조산과 태아감염 및 태아손상을 산전 진단하기 위한진단시약 및 진단키트
WO2002043578A2 (en) * 2000-11-28 2002-06-06 Children's Medical Center Corporation Determination of risk and treatment of complications of prematurity
JP2004521901A (ja) 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ阻害剤としてのピラゾール
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
ATE291020T1 (de) 2001-02-02 2005-04-15 Smithkline Beecham Corp Pyrazolderivate gegen tgf überexprimierung
GB0102673D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102665D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
DE60221392T2 (de) 2001-05-24 2008-04-17 Eli Lilly And Co., Indianapolis Neue pyrrolderivate als pharmazeutische mittel
EP1478354A4 (en) 2002-01-22 2008-09-24 Genzyme Corp USE OF TGF-BETA ANTAGONISTS IN THE TREATMENT OR PREVENTION OF CHRONIC RELEASE OF TRANSPLANT
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
JP2005530800A (ja) 2002-05-15 2005-10-13 スミスクライン・ビーチャム・コーポレイション ベンゾオキサジンおよびベンゾオキサジノン置換トリアゾール
EP1511738A4 (en) 2002-05-17 2007-05-09 Scios Inc TREATMENT OF FIBROPROLIFERATIVE DISEASES USING TGF BETA INHIBITORS
AU2003256783A1 (en) 2002-07-25 2004-02-16 Scios, Inc. METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-Beta INHIBITORS
GB0217786D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
EP1549316A4 (en) 2002-09-10 2008-04-09 Scios Inc HAMMER OF TFGbeta
WO2004026871A1 (en) 2002-09-17 2004-04-01 Eli Lilly And Company Novel pyrazolopyridine derivatves as pharmaceutical agents
WO2004026302A1 (en) 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
JP2006524633A (ja) 2002-11-22 2006-11-02 サイオス・インコーポレーテツド β−アドレナリン作動性経路における病理学的変化を打ち消すための方法
US20040138188A1 (en) 2002-11-22 2004-07-15 Higgins Linda S. Use of TGF-beta inhibitors to counteract pathologic changes in the level or function of steroid/thyroid receptors
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
US20060079680A1 (en) 2002-11-22 2006-04-13 Eli Lilly And Company Patent Division Pyrazoloazepine compounds as pharmaceutical agents
WO2004050659A1 (en) 2002-11-27 2004-06-17 Eli Lilly And Company Novel compounds as pharmaceutical agents
JP2006512369A (ja) 2002-12-19 2006-04-13 サイオス・インコーポレーテツド ＴＧＦ−β阻害剤を用いる肥満症および関連症状の処置
CA2512989A1 (en) 2003-02-06 2004-08-26 Adeza Biomedical Corporation Screening and treatment methods for prevention of preterm delivery
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
WO2004087056A2 (en) 2003-03-28 2004-10-14 Scios Inc. BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
WO2005065691A1 (en) 2003-12-24 2005-07-21 Scios, Inc. Treatment of malignant gliomas with tgf-beta inhibitors
EP1723146A1 (en) 2004-03-01 2006-11-22 Eli Lilly And Company Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
ZA200608130B (en) * 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
DE102004019253A1 (de) 2004-04-16 2005-11-10 Codewrights Gmbh Verfahren zum Fernbedienen eines Feldgerätes der Prozessautomatisierungstechnik
MX2007001589A (es) * 2004-08-09 2007-08-02 Alios Biopharma Inc Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
CA2578630A1 (en) 2004-08-31 2006-03-09 Wen-Cherng Lee Pyrimidinylimidazoles as tgf-beta inhibitors
EP1786803A1 (en) 2004-08-31 2007-05-23 Biogen Idec MA, Inc. Pyrimidinylpyrazoles as tgf-beta inhibitors
EP1812450A2 (en) 2004-11-10 2007-08-01 Eli Lilly And Company Tgf-beta inhibitors
AU2006213875B2 (en) * 2005-02-08 2010-08-19 Genzyme Corporation Antibodies to TGFBETA

Also Published As

Publication number Publication date
PL2083863T3 (pl) 2015-08-31
HUE035575T2 (en) 2018-05-28
US20100008911A1 (en) 2010-01-14
EP2918288B1 (en) 2017-08-16
WO2008060371A8 (en) 2008-07-10
US20170233464A1 (en) 2017-08-17
EP3254696A1 (en) 2017-12-13
IL197797A (en) 2017-05-29
DK2083863T3 (da) 2015-06-22
US8642034B2 (en) 2014-02-04
EP2083863B1 (en) 2015-03-18
IL197797A0 (en) 2011-08-01
DK2918288T3 (da) 2017-11-27
EP2918288A1 (en) 2015-09-16
IL251994A0 (en) 2017-06-29
PL2918288T3 (pl) 2018-02-28
CN104645328A (zh) 2015-05-27
IL251994B (en) 2021-01-31
WO2008060371A1 (en) 2008-05-22
EP2083863A1 (en) 2009-08-05
US20140199399A1 (en) 2014-07-17
CN101553254A (zh) 2009-10-07
ES2647472T3 (es) 2017-12-21
ES2538265T3 (es) 2015-06-18

Similar Documents

Publication Publication Date Title
MX2009003518A (es) Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
MY156913A (en) Oral administration of peripherally-acting opioid antagonists
EA201490876A1 (ru) Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
MX2021002322A (es) Nuevos metodos.
MY145999A (en) Preventing diseases in infants delivered via caesarean section
BR112018067906A2 (pt) métodos de tratamento de depressão usando antagonistas do receptor de orexina-2
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
MY199017A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2014093127A3 (en) Method of administering nicotine, thc, tobacco, cannabidiol or base alkaloid and absorption conditioning unit
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
MY178654A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy
NZ576424A (en) Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
EA201100409A1 (ru) Замещенные производные триазолопиридазина
PH12018500023A1 (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
AR091351A1 (es) Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion
PH12012500895A1 (en) Method for treating heart failure with stresscopin-like peptides
MX2024013184A (es) Metodos y composiciones para tratar apnea del sue?o
BR112016028973A2 (pt) composições antagonistas de receptor de sabor doce
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
MX2009009332A (es) Antagonista del receptor de mineralocorticoides para el tratamiento de endometriosis.
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
IN2014MN02156A (es)
MY182801A (en) Compound for activating ampk and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration